Management of post-acute covid-19 in primary care

This is not an experimental study but a clinical review article. The authors did not test an intervention. Instead, they:

Reviewed existing (limited) evidence on the natural history of post-acute COVID-19

Synthesised clinical guidance for primary care practitioners managing patients 3–12 weeks after initial infection

Proposed a framework for assessment, monitoring, and referral based on symptom clusters (respiratory, cardiac, neurological, musculoskeletal, psychological)

Recommended specific monitoring tools (home pulse oximetry) and management strategies (pacing, graded return to activity, symptomatic treatment)

The "comparator" is implicit: usual care without structured follow-up versus the proposed systematic approach to post-COVID assessment and monitoring.

Outcome measures discussed include:

Resolution of symptoms (cough, breathlessness, fatigue, chest pain, palpitations, brain fog, anosmia)

Oxygen saturation (SpO₂) trends over time

Exercise tolerance (subjective, not formally measured)

Need for specialist referral (based on clinical concern plus new/persistent/progressive symptoms in respiratory, cardiac, or neurological systems)

This is not a primary study with enrolled participants. The review draws on:

Early pandemic data (primarily from China, Italy, UK) on hospitalised COVID-19 patients

Community-based observational data suggesting ~10% of non-hospitalised patients have symptoms beyond 3 weeks

Expert consensus from UK primary care clinicians and specialists

No specific sample size — the review synthesises multiple small studies and case series, most with fewer than 200 patients

The population of interest is adults (18+) who have had confirmed or suspected COVID-19 and remain symptomatic beyond 3 weeks from symptom onset. The review explicitly notes that most available data comes from hospitalised patients, which may not generalise to the majority of COVID-19 cases managed in the community.

No formal measurements were taken in this review. The authors discuss:

**Home pulse oximetry:** Using a fingertip pulse oximeter to measure SpO₂. Normal is 95–100%. They recommend monitoring trends rather than single readings, and flagging sustained drops below 94% or drops of ≥3% from baseline.

**Symptom diaries:** Self-reported tracking of breathlessness, cough, fatigue, chest tightness, palpitations, and cognitive function (brain fog).

**Clinical examination:** Chest auscultation, heart rate and rhythm assessment, oxygen saturation, blood pressure, and neurological examination (cranial nerves, peripheral sensation, coordination).

**Basic investigations:** Full blood count, C-reactive protein, ferritin, D-dimer, electrocardiogram (ECG), and chest X-ray — but the review notes these are often normal in post-acute COVID-19.

**No validated post-COVID symptom scale existed at time of publication** — the authors recommend using the Medical Research Council (MRC) dyspnoea scale (1–5, where 1 = no breathlessness except with strenuous exercise, 5 = too breathless to leave the house) as a pragmatic tool.

### Study design

This is a **clinical review** — a narrative synthesis of available evidence combined with expert clinical opinion. It is not a systematic review, meta-analysis, randomised controlled trial, or observational cohort study. The authors explicitly state that "management of covid-19 after the first three weeks is currently based on limited evidence."

### How evidence was gathered

The authors searched PubMed and preprint servers for studies on COVID-19 outcomes beyond 3 weeks, supplemented by their own clinical experience managing post-COVID patients in UK primary care during the first wave (March–July 2020). They do not report a formal search strategy, inclusion/exclusion criteria, or quality assessment of included studies.

### What this design can and cannot prove

**What it can do:**

Summarise current knowledge (or lack thereof) in a rapidly evolving field

Provide practical guidance when no high-quality evidence exists

Identify key uncertainties and research priorities

Offer a framework for clinical decision-making based on expert consensus

**What it cannot do:**

Prove that any specific intervention is effective

Establish causal relationships between symptoms and underlying pathophysiology

Provide precise estimates of prevalence, duration, or prognosis

Compare the effectiveness of different management strategies

Rule out placebo effects or natural recovery

### Major methodological weaknesses

**No systematic search:** The authors do not report search terms, databases, date ranges, or number of studies screened. This introduces selection bias — they may have preferentially included studies that support their views.

**No quality assessment:** Studies of varying quality are given equal weight. Early pandemic studies had small samples, short follow-up, and high loss to follow-up.

**No meta-analysis:** Effect sizes cannot be pooled or compared.

**Reliance on hospital data:** Most evidence comes from hospitalised patients, yet the guidance is aimed at primary care where most patients were never hospitalised.

**Outdated by definition:** Published August 2020, this review predates the emergence of variants (Alpha, Delta, Omicron), vaccination programmes, and large-scale cohort studies like the UK's PHOSP-COVID and COVIDENCE UK.

**No patient-reported outcome measures:** The review does not incorporate patient experience data or validated quality-of-life instruments.

The review does not report statistical findings from a single study. Instead, it presents clinical observations and consensus recommendations:

**Prevalence of prolonged illness:** Approximately 10% of people with COVID-19 experience symptoms beyond 3 weeks. This estimate comes from early community surveillance data and is acknowledged as uncertain.

**Natural history:** Many patients recover spontaneously, but recovery can be slow (weeks to months). The review does not provide specific timelines or proportions.

**Symptom clusters identified:**

- Respiratory: persistent cough, breathlessness, reduced exercise tolerance

- Cardiac: chest tightness, palpitations, chest pain

- Neurological: brain fog, headache, dizziness, peripheral neuropathy, anosmia/dysgeusia

- Musculoskeletal: myalgia, joint pain, fatigue

- Psychological: anxiety, depression, PTSD, sleep disturbance

**Home pulse oximetry:** The authors recommend monitoring SpO₂ trends. They suggest that a sustained drop below 94% or a drop of ≥3% from baseline warrants clinical review. No sensitivity or specificity data are provided for this threshold.

**Indications for specialist referral:** New, persistent, or progressive symptoms in respiratory, cardiac, or neurological systems, plus clinical concern (e.g., abnormal vital signs, inability to self-care, worsening trajectory).

**Management approach:** Holistic support, rest, symptomatic treatment (paracetamol for pain/fever, antitussives for cough), and gradual increase in activity. No specific pharmacological or rehabilitation interventions are recommended due to lack of evidence.

**Return to activity:** The authors caution against "push-through" mentality and recommend pacing — breaking activities into smaller chunks with rest periods. They suggest a 50% rule: if an activity leaves you exhausted the next day, reduce it by half.

**No evidence for:** Antivirals, corticosteroids, anticoagulants, or immunomodulators in the post-acute phase (unless specific complications are identified).

Because this is a clinical review rather than an experimental study, there are no effect sizes, confidence intervals, or p-values to report. The key numerical claim is:

**~10% prevalence of prolonged symptoms** — meaning that in a group of 100 people with COVID-19, roughly 10 will still have symptoms after 3 weeks. For context, this is similar to the proportion of people who experience prolonged symptoms after other viral illnesses (e.g., Epstein-Barr virus, Q fever), though the review does not provide comparative data.

The review's recommendations are based on clinical plausibility and expert opinion, not on demonstrated effect sizes. For example:

The recommendation for home pulse oximetry is based on the observation that some patients with COVID-19 develop "silent hypoxia" (low oxygen without proportionate breathlessness). The magnitude of benefit (e.g., how many cases of deterioration are detected earlier) is unknown.

The pacing recommendation is extrapolated from chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) management, where it has modest evidence (small RCTs showing improved function but no cure). The effect size in post-COVID patients has not been studied.

### What the authors acknowledge

"Management of covid-19 after the first three weeks is currently based on limited evidence"

Most data comes from hospitalised patients, not community-managed cases

The natural history of post-acute COVID-19 is poorly understood

Recommendations are based on clinical experience and extrapolation from other post-viral syndromes

The review does not address children, pregnant women, or immunocompromised patients

### What a critical reader would note

**No systematic methodology:** Without a reproducible search strategy, the review cannot be updated or verified. Important studies may have been missed.

**Publication date:** August 2020 — this is very early in the pandemic. Subsequent research has substantially changed our understanding of long COVID (now known to affect 10–30% of non-hospitalised cases, with symptoms lasting >12 weeks in many).

**No patient involvement:** The review does not include patient perspectives, despite long COVID patient advocacy groups (e.g., Long Covid SOS, Body Politic) being active by mid-2020.

**No discussion of sex/gender differences:** Subsequent research shows long COVID is more common in women (by ~1.5–2x), but this is not mentioned.

**No discussion of reinfection or vaccination effects:** These were unknown at the time but are now critical considerations.

**No validated diagnostic criteria:** The review proposes symptom clusters but does not offer a case definition. The WHO clinical case definition for post-COVID-19 condition was not published until October 2021.

**Potential for harm:** The recommendation for "gradual increase in activity" without specific guidance on heart rate monitoring or post-exertional malaise could lead to symptom exacerbation in patients with post-exertional symptom exacerbation (a hallmark of long COVID, now well-documented).

**Industry funding:** Not declared, but no pharmaceutical or device company involvement is mentioned. The review is likely independent.

For someone running their own n=1 experiment to manage post-COVID symptoms:

### What to test

**Pacing protocol:** Structured activity-rest cycling. Test: 3 weeks of "50% rule" (if an activity leaves you exhausted the next day, reduce it by half) versus your current approach of doing as much as you can.

**Home pulse oximetry monitoring:** Test: daily SpO₂ readings at rest and after a standardised 1-minute step test (step up and down on a 20cm step 20 times). Track trends over 2 weeks.

**Symptom-specific interventions (one at a time):**

- For breathlessness: Pursed-lip breathing (inhale through nose for 2 counts, exhale through pursed lips for 4 counts), 5 minutes, 3x daily

- For brain fog: 10-minute mindfulness meditation twice daily

- For fatigue: Scheduled rest periods (20 minutes, lying down, no screens) every 2–3 hours

**Supplements (if desired):** Vitamin D (1000–2000 IU/day) or coenzyme Q10 (200 mg/day) — but be aware evidence is weak

### Minimum meaningful duration

**For pacing:** 3–4 weeks minimum. Post-exertional symptom exacerbation can have a 24–72 hour delay, so you need at least 2 weeks of consistent data to see patterns.

**For pulse oximetry:** 2 weeks of daily readings to establish your personal baseline and trend.

**For any single intervention:** 2 weeks at a consistent dose/frequency, followed by 1 week washout before testing something else.

### What to measure (specific metrics)

**Daily symptom score:** Rate 5 core symptoms (fatigue, breathlessness, brain fog, muscle pain, cough) on 0–10 scale each evening (0 = none, 10 = worst imaginable)

**Activity tolerance:** Record minutes of continuous walking or standing before symptoms force you to stop. Do a standardised 6-minute walk test once weekly (walk as far as you can in 6 minutes on flat ground, measure distance in metres)

**Oxygen saturation:** Resting SpO₂ and post-step-test SpO₂ (lowest reading within 2 minutes of finishing). Record daily at same time of day.

**Heart rate:** Resting heart rate (on waking, before getting up) and heart rate recovery (heart rate 1 minute after stopping the step test). A delayed recovery (>12 beats drop in first minute) suggests deconditioning or dysautonomia.

**Cognitive function:** Use a free online Stroop test or digit span test (e.g., from Cambridge Brain Sciences or BrainHQ) — do the same 5-minute test at the same time each day. Track reaction time and accuracy.

**Sleep quality:** Wake time, sleep onset latency (minutes to fall asleep), number of night awakenings, and subjective refreshment on waking (0–10 scale)

### Key confounds to control for

**Menstrual cycle phase:** Symptoms (especially fatigue and brain fog) can vary with oestrogen/progesterone. Track cycle phase or use a period tracker app. Compare same phase to same phase.

**Stress levels:** Daily stress (work, family, finances) can mimic or worsen post-COVID symptoms. Rate stress on 0–10 scale daily.

**Sleep debt:** A single bad night can ruin your data. Record sleep duration and quality each night. Exclude days after <5 hours sleep from analysis.

**Activity the previous day:** Post-exertional symptom exacerbation means today's symptoms may reflect yesterday's activity, not today's. Always lag your activity data by 1 day when looking for patterns.

**Hydration and nutrition:** Dehydration worsens fatigue and brain fog. Log water intake (aim for 2L/day) and whether you ate a balanced meal.

**Medication changes:** Any new medication (including over-the-counter) can affect symptoms. Record all meds and doses.

**Time of day:** Symptoms fluctuate. Measure at the same time each day (e.g., 7pm for symptom scores, 8am for resting heart rate).

### What a positive result would look like

**For pacing:** After 3 weeks, your daily symptom scores are consistently 2+ points lower (on 0–10 scale) than your 1-week baseline, AND your 6-minute walk distance has increased by ≥30 metres (the minimal clinically important difference for post-COVID recovery).

**For pulse oximetry:** Your resting SpO₂ is stable at ≥96% (if it was lower before), and your post-step-test SpO₂ does not drop below 94% (if it previously did). Your heart rate recovery improves by ≥5 beats in the first minute.

**For any single intervention:** You see a clear pattern: symptoms improve within 2–3 days of starting the intervention, worsen within 2–3 days of stopping it, and improve again when restarting (A-B-A design). The improvement is ≥30% reduction in your primary symptom (e.g., fatigue drops from 7/10 to 4/10 or lower).

**Red flag (negative result):** If your resting SpO₂ drops below 94% on two consecutive days, or your 6-minute walk distance decreases by ≥30 metres from baseline, stop self-experimenting and seek medical assessment.

### Important caveat

This review was published in August 2020. Since then, large cohort studies (e.g., PHOSP-COVID, COVIDENCE UK, the RECOVER initiative in the US) have substantially advanced our understanding of long COVID. For current guidance, consult:

NICE guideline NG188 (published December 2020, updated 2024)

WHO clinical case definition for post-COVID-19 condition (October 2021)

Patient-led research collaboratives (e